Medifast (NYSE: MED) reported Q4 EPS of $2.91, $0.26 better than the analyst estimate of $2.65. Revenue for the quarter came in at $377.8 million versus the consensus estimate of $375.79 million.

GUIDANCE:

Medifast sees FY2022 EPS of $14.50-$16.00, versus the consensus of $15.96. Medifast sees FY2022 revenue of $1.72-1.79 billion, versus the consensus of $1.74 billion.

• The Company expects full-year 2022 revenue to be in the range of $1.72 billion to $1.79 billion and full-year 2022 diluted EPS to be in the range of $14.50 to $16.00. The full-year 2022 earnings guidance assumes a 24.25% to 25.25% effective tax rate.

For earnings history and earnings-related data on Medifast (MED) click here.